A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects.
Saved in:
| Title: | A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. |
|---|---|
| Authors: | Voderholzer, U., Riemann, D., Hornyak, M., Backhaus, J., Feige, B., Berger, M., Hohagen, F. |
| Source: | European Archives of Psychiatry & Clinical Neuroscience. 2001, Vol. 251 Issue 3, p117. 7p. |
| Subjects: | Polysomnography, Hypnotics, Zolpidem, Placebos, Physiology |
| Abstract: | Rebound effects after withdrawal from hypnotics are believed to trigger their chronic use and to enhance the risk of tolerance and dependence. It was the purpose of this study to investigate the acute polysomnographic withdrawal effects after a 4 week treatment with standard doses of the non-benzodiazepine hypnotics zopiclone and zolpidem compared with triazolam and placebo. Healthy male subjects between 22 and 35 years of age participated in a parallel study design. They received either zopiclone 7.5 mg (n=11), zolpidem 10 mg (n=11), triazolam 0.25 mg (n=10) or placebo (n=7) over 4 weeks in randomized and double-blind order. Sleep EEG was registered during 2 nights before treatment under placebo, on days 1, 27 and 28 of treatment and on days 29, 30, 41 and 42 under placebo. Total sleep time and sleep efficiency were lower in the 1[sup st] night after discontinuation of triazolam (p < 0.05, t-test). After withdrawal from zopiclone or zolpidem slight but not significant rebound effects concerning sleep continuity were observed. Self-rating scales showed minimal rebound insomnia after discontinuation of all three hypnotics. In the placebo group no changes of sleep parameters were observed. Assuming that rebound insomnia is part of a withdrawal reaction, this study indicates that the risks of tolerance and dependency are low when administering zopiclone or zolpidem at the recommended doses. [ABSTRACT FROM AUTHOR] |
| Copyright of European Archives of Psychiatry & Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 5352213 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Voderholzer%2C+U%2E%22">Voderholzer, U.</searchLink><br /><searchLink fieldCode="AR" term="%22Riemann%2C+D%2E%22">Riemann, D.</searchLink><br /><searchLink fieldCode="AR" term="%22Hornyak%2C+M%2E%22">Hornyak, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Backhaus%2C+J%2E%22">Backhaus, J.</searchLink><br /><searchLink fieldCode="AR" term="%22Feige%2C+B%2E%22">Feige, B.</searchLink><br /><searchLink fieldCode="AR" term="%22Berger%2C+M%2E%22">Berger, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Hohagen%2C+F%2E%22">Hohagen, F.</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22European+Archives+of+Psychiatry+%26+Clinical+Neuroscience%22">European Archives of Psychiatry & Clinical Neuroscience</searchLink>. 2001, Vol. 251 Issue 3, p117. 7p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Polysomnography%22">Polysomnography</searchLink><br /><searchLink fieldCode="DE" term="%22Hypnotics%22">Hypnotics</searchLink><br /><searchLink fieldCode="DE" term="%22Zolpidem%22">Zolpidem</searchLink><br /><searchLink fieldCode="DE" term="%22Placebos%22">Placebos</searchLink><br /><searchLink fieldCode="DE" term="%22Physiology%22">Physiology</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Rebound effects after withdrawal from hypnotics are believed to trigger their chronic use and to enhance the risk of tolerance and dependence. It was the purpose of this study to investigate the acute polysomnographic withdrawal effects after a 4 week treatment with standard doses of the non-benzodiazepine hypnotics zopiclone and zolpidem compared with triazolam and placebo. Healthy male subjects between 22 and 35 years of age participated in a parallel study design. They received either zopiclone 7.5 mg (n=11), zolpidem 10 mg (n=11), triazolam 0.25 mg (n=10) or placebo (n=7) over 4 weeks in randomized and double-blind order. Sleep EEG was registered during 2 nights before treatment under placebo, on days 1, 27 and 28 of treatment and on days 29, 30, 41 and 42 under placebo. Total sleep time and sleep efficiency were lower in the 1[sup st] night after discontinuation of triazolam (p < 0.05, t-test). After withdrawal from zopiclone or zolpidem slight but not significant rebound effects concerning sleep continuity were observed. Self-rating scales showed minimal rebound insomnia after discontinuation of all three hypnotics. In the placebo group no changes of sleep parameters were observed. Assuming that rebound insomnia is part of a withdrawal reaction, this study indicates that the risks of tolerance and dependency are low when administering zopiclone or zolpidem at the recommended doses. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of European Archives of Psychiatry & Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=5352213 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s004060170045 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 7 StartPage: 117 Subjects: – SubjectFull: Polysomnography Type: general – SubjectFull: Hypnotics Type: general – SubjectFull: Zolpidem Type: general – SubjectFull: Placebos Type: general – SubjectFull: Physiology Type: general Titles: – TitleFull: A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Voderholzer, U. – PersonEntity: Name: NameFull: Riemann, D. – PersonEntity: Name: NameFull: Hornyak, M. – PersonEntity: Name: NameFull: Backhaus, J. – PersonEntity: Name: NameFull: Feige, B. – PersonEntity: Name: NameFull: Berger, M. – PersonEntity: Name: NameFull: Hohagen, F. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2001 Type: published Y: 2001 Identifiers: – Type: issn-print Value: 09401334 Numbering: – Type: volume Value: 251 – Type: issue Value: 3 Titles: – TitleFull: European Archives of Psychiatry & Clinical Neuroscience Type: main |
| ResultId | 1 |
